# Ascend Wellness Holdings, Inc. (AAWH)

**Exchange:** OTC  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/AAWH/primer

## Business Model

---
source: coverage-next-full
ticker: AAWH
step: 01
title: Business Model Overview
date: 2026-06-03
---

### Step 01 — Business Model Overview: Ascend Wellness Holdings (AAWH)

#### Business Description [S1]

Ascend Wellness Holdings, Inc. is a vertically integrated Multi-State Cannabis Operator (MSO) founded in 2018 and headquartered in Morristown, New Jersey. The company cultivates, manufactures, and retails cannabis products across seven US states through owned dispensaries and a growing wholesale distribution network. [S1: 10-K FY2024 — Business Description]

AAWH operates primarily in limited-license markets — states where the number of cannabis cultivators, processors, and retailers is capped by regulation — which historically supported higher price points and margins than open-license states. As of Q1 2026, AAWH operates 51 retail dispensary locations and sells wholesale cannabis to third-party dispensaries. [S2: Q1 2026 earnings press release]

---

#### Value-Chain Layer Map

| Layer | AAWH Activity | Revenue Contribution (est.) | Notes |
|-------|--------------|----------------------------|-------|
| **Cultivation** | Owned grows in NJ, IL, OH, MA, MI, PA | Internal — feeds both retail + wholesale | Vertical integration reduces COGS vs. wholesale-only |
| **Processing / Manufacturing** | Extraction, infused products, packaging | Internal | Branded products (OZONE, Kiva) + white-label |
| **Wholesale Distribution** | B2B sales to third-party dispensaries | ~29% of FY2024 revenue (~$163M) | Fast-growing segment; +28.5% YoY in FY2024 |
| **Retail Dispensary** | 51 company-owned dispensary locations | ~71% of FY2024 revenue (~$399M) | Core business; direct-to-consumer |

[S3: 10-K FY2024 — Segment reporting, MD&A]

---

#### State Footprint (as of Q1 2026)

| State | Type | Status | Key Notes |
|-------|------|--------|-----------|
| New Jersey | Medical + Adult-Use | Core market | Adult-use launched April 2022; NJ is AAWH's largest wholesale market |
| Illinois | Medical + Adult-Use | Core market | Mature, competitive; revenue headwind |
| Ohio | Medical + Adult-Use | High-growth | Adult-use launched Dec 2023; AAWH saw ~3x sales increase |
| Michigan | Adult-Use | Competitive | Lower-margin open-license market |
| Massachusetts | Medical + Adult-Use | Established | Limited-license legacy market |
| Pennsylvania | Medical only | Pending adult-use | Medical-only; adult-use vote pending |
| Maryland | Adult-Use | Relatively new | Adult-use launched July 2023 |

[S4: 10-K FY2024 — Properties; press releases Q3–Q4 2024]

---

#### Revenue Architecture

##### Retail vs. Wholesale Split

| Year | Retail Revenue | Wholesale Revenue | Total | Wholesale % |
|------|---------------|------------------|-------|-------------|
| FY2022 | ~$280M | ~$126M | $405.9M | 31% |
| FY2023 | ~$367M | ~$152M | $518.6M | 29% |
| FY2024 | ~$399M | ~$163M | $561.6M | 29% |
| FY2025 | ~$345M | ~$156M | $500.6M | 31% (est.) |

[S5: 10-K FY2024 disaggregated revenue note; FY2025 estimates from press releases]

---

#### Product Portfolio

| Category | Brands / Notes |
|----------|---------------|
| Flower | AAWH house brands + third-party |
| Pre-rolls | Fastest-growing format across the industry |
| Concentrates / Vapes | High-margin; OZONE brand |
| Edibles / Beverages | Kiva partnership; infused gummies, chocolates |
| Topicals / Tinctures | Medical market focus |

AAWH launched 566 new SKUs in FY2025, indicating active product development. [S6: FY2025 earnings PR]

---

#### Economic Model

**Unit economics (retail dispensary):**
- Average revenue per location (FY2024): ~$562M ÷ 39 locations ≈ $14.4M/location/year
- Gross margin: 32.8% (FY2024), improving to 38.4% (Q1 2026)
- Adj. EBITDA margin: 20.7% (FY2024), 23.4% (FY2025)
- Key COGS driver: cultivation + processing costs; improving as operational leverage scales

**280E structural drag:**
- Under IRC §280E, plant-touching cannabis companies cannot deduct ordinary business expenses (SG&A, depreciation, interest) for federal tax purposes. AAWH pays ~$45–51M/year in income taxes despite reporting GAAP net losses. This is the central distortion in GAAP income metrics — EPS and net income are not meaningful for comparability until 280E is resolved. [S7: 10-K FY2024 — Tax footnote]

---

#### Customer / Market

**Customers:** Retail — individual consumers (medical patients + adult-use recreational). Wholesale — licensed dispensary operators in AAWH's states.

**Market structure:** Limited-license states dominate AAWH's footprint, which creates meaningful barriers to entry for new competitors but also caps TAM growth as license caps are set by regulators. Ohio adult-use (late 2023 legalization) represents the most recent TAM expansion.

---

#### Thesis Tracker Update

Step 01 reinforces the core thesis: AAWH is a retail-heavy MSO with a growing wholesale segment, operating in limited-license markets that provide some pricing power. The 280E tax drag is structural and severe — it is the primary distortion in GAAP financials and the central catalyst if resolved. The 71%/29% retail/wholesale mix provides two revenue vectors. Ohio adult-use ramp is the key near-term organic growth driver.

---

#### Source Index

| Code | Source |
|------|--------|
| S1 | 10-K FY2024 — Business Description section |
| S2 | Q1 2026 Earnings Press Release (May 2026) — Operational highlights |
| S3 | 10-K FY2024 — Note on Revenue Disaggregation + MD&A |
| S4 | 10-K FY2024 — Properties section + press releases |
| S5 | 10-K FY2024 + FY2025 earnings press releases — Revenue segment data |
| S6 | FY2025 Earnings Press Release (March 2026) |
| S7 | 10-K FY2024 — Income Tax note (IRC §280E discussion) |

## Financial Snapshot

---
source: coverage-next-full
ticker: AAWH
step: 04
title: Financial Quality & Adversarial Sweep
date: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Ascend Wellness Holdings (AAWH)

#### Financial Statement Quality Assessment [S1]

##### Income Statement Quality

AAWH's GAAP income statement requires significant adjustment to be analytically useful due to IRC §280E. Key adjustments:

| Item | GAAP Treatment | Adjustment Needed | Notes |
|------|---------------|-------------------|-------|
| Revenue | Clean — recognized on dispensary sales/wholesale delivery | None | Reliable |
| Cost of Revenue | Includes only COGS (cultivation/production); cannot deduct SG&A | None — COGS only | 280E means SG&A must stay above the line |
| Gross Profit | Clean | None | Comparable across years |
| G&A / SG&A | Full operating expense | None — but compare to Adj. EBITDA | Non-deductible for 280E purposes |
| Income Tax | Paid on gross profit, not net income (280E) | Remove for economic analysis | $45–51M/yr is non-economic tax drag |
| Net Income | Severely distorted by 280E | Use Adj. EBITDA instead | Not comparable to non-cannabis peers |

**Conclusion:** Revenue and Gross Profit are clean metrics. Adj. EBITDA is the primary measure of economic performance. Net income/EPS are structurally impaired by 280E and should not be used for valuation or trend analysis.

##### Balance Sheet Quality

| Item | Assessment |
|------|-----------|
| Cash ($60.9M at Q1'26) | Reliable; confirmed in 10-Q filings |
| Goodwill ($58.4M) | Moderate — accumulated from acquisitions; no impairment recorded recently |
| Inventory (~$50–60M est.) | Cannabis inventory; subject to state destruction/expiration risk; typically conservative |
| Long-Term Debt ($318.9M) | Senior secured notes at 9.5% due July 2029; well-documented in 10-K |
| Lease Obligations | Significant — cannabis companies cannot own real estate under federal law; all locations are leased |
| Negative Equity ($(76.6)M) | Driven by cumulative 280E tax losses, not economic value destruction; total assets still $872M |

**Key balance sheet flag:** Stockholders' equity turned negative in Q4 2025. This is primarily a GAAP accounting artifact of 280E — the company has been paying taxes on gross profit for years while reporting net losses, depleting retained earnings. It does not mean the business is economically worthless (assets of $872M vs. liabilities of $948M). However, it does create covenant risk and limits refinancing flexibility.

##### Cash Flow Quality

| Item | FY2024 | FY2025 | Notes |
|------|--------|--------|-------|
| Operating Cash Flow | ~$63M est. | ~$38M | Declining but positive |
| Capex | ~$20M | ~$26M | Organic expansion |
| Free Cash Flow | ~$43M est. | ~$12M | Declining sharply |
| FCF as % of Adj. EBITDA | ~37% | ~10% | Compression trend |

FCF compression is concerning — interest expense (~$51M/yr) now exceeds annual FCF ($12M). The company is consuming cash on an economic basis despite positive Adj. EBITDA. If revenue continues to decline without cost reduction, FCF could turn negative in FY2026.

---

#### Adversarial Research Sweep [S2]

*Note: No earnings transcripts used; adversarial research conducted via web search, SEC filings review, and public records.*

##### Short Interest / Bearish Theses

**Primary bear thesis circulating in public forums:**
1. **Revenue decline is structural, not cyclical.** Bear argument: Illinois and Michigan are permanently oversupplied markets; Ohio is now also trending toward over-licensing. Revenue recovery is not assured.
2. **Leverage is unsustainable.** Net debt of $216M vs. $12M FCF means the company cannot service debt from operations at current trajectory. If FCF turns negative, AAWH may need to raise dilutive equity.
3. **Schedule III rescheduling could disappoint.** The rescheduling process has been through multiple delays; bears argue 280E elimination may be later than market expects or get tied up in legal challenges.
4. **Negative equity creates covenant risk.** Senior note covenants may be tested if EBITDA declines further; technical default risk is non-trivial.
5. **OTC listing limits institutional ownership.** AAWH cannot uplift to Nasdaq/NYSE while cannabis remains federally illegal, keeping a large buyer pool permanently on the sidelines.

##### Investigations, Lawsuits, Controversies

**SEC/Regulatory investigations:** No material SEC enforcement actions identified in filings or public records search. [S2: 10-K FY2024 — Legal Proceedings; web search]

**Class action lawsuits:** No active securities class action lawsuits identified. Historical: AAWH settled routine commercial disputes in 2022–2023 (details in 10-K legal proceedings note; amounts not material).

**$17M Arbitration Reserve (FY2025):** AAWH disclosed a $17M arbitration reserve in FY2025 related to a commercial dispute. This was resolved in Q1 2026. Not a going-concern event. [S3: Q1 2026 PR — "resolution of $17M arbitration reserve"]

**Management turnover:** CEO and CFO were both replaced in August 2024 — significant change within 12 months. New CEO: Samuel Brill (previously EVP Strategy). New CFO: Roman Nemchenko (internal promotion from CAO). Leadership transitions create execution risk during a period of industry headwinds. [S4: Governance file]

**Auditor change (March 2025):** Macias Gini dismissed; WithumSmith+Brown appointed. Auditor changes are a yellow flag; no accounting restatements identified. Withum is a reputable mid-market auditor with cannabis sector expertise. [S5: SEC 8-K — March 2025]

**Dual-class share structure:** Founders retain super-voting rights through a dual-class structure. CEO Abner Kurtin (chair/co-founder) and co-founder Frank Perullo control significant voting power disproportionate to economic stake. This creates governance risk but is standard in the cannabis sector. [S6: Governance file]

##### Cannabis-Specific Compliance Risks

| Risk | Status |
|------|--------|
| State license compliance | No disclosed license revocations; routine renewals ongoing |
| DEA/DOJ enforcement | De minimis risk under current federal policy (enforcement deprioritized for compliant state operators) |
| Track-and-trace compliance | Required in all AAWH states; company uses standard compliance systems |
| Multi-state licensing continuity | Ongoing regulatory requirement; no disclosed failures |

---

#### Accounting Adjustments for Analysis

The most important adjustments for analyzing AAWH:
1. **Remove 280E income tax from all comparative analysis** — use Adj. EBITDA, not GAAP net income.
2. **Add back non-cash lease expense** where relevant (cannabis leases are significant and non-standard).
3. **Treat goodwill ($58M) as potentially impaired** if any state licenses are lost — goodwill is largely license-acquisition premium.
4. **FCF = Operating Cash Flow - Capex** is the most reliable near-term cash generation signal.

---

#### Thesis Tracker Update

Step 04 confirms the bear case thesis is primarily execution-risk based (revenue decline, leverage) and catalyst-timing based (280E rescheduling delay). The bull case is that the discount (~2.1x EV/EBITDA vs. 4–5x peers) overcompensates for these risks given: (a) debt is refinanced to 2029 with no near-term maturity, (b) $116M Adj. EBITDA provides a real earnings cushion, (c) 280E elimination could add $45–50M in after-tax cash flow. The auditor change and management turnover are yellow flags, not red flags.

---

#### Source Index

| Code | Source |
|------|--------|
| S1 | SEC XBRL + 10-K FY2024 — financial statement analysis |
| S2 | 10-K FY2024 — Legal Proceedings; web search for short reports |
| S3 | Q1 2026 Earnings Press Release — arbitration resolution |
| S4 | proxy/governance_and_compensation.md — management changes |
| S5 | SEC EDGAR 8-K search — auditor change disclosure |
| S6 | proxy/governance_and_compensation.md — dual-class structure |

## Recent Catalysts

---
source: coverage-next-full
ticker: AAWH
step: 12
title: Bull vs. Bear — Analyst Debate
date: 2026-06-03
---

### Step 12 — Bull vs. Bear: Ascend Wellness Holdings (AAWH)

*Note: Earnings transcript analysis was NOT performed — this is the filings-and-consensus path. The bull/bear debate is inferred from consensus notes, press releases, filings, and industry analysis. The analytical framework follows the analyst-debate spec.*

---

#### Central Debate

The core dispute on AAWH is whether the stock's ~2.1x EV/Adj. EBITDA discount to peers (sector median 4–5x) represents: (a) a rational pricing of structural risks (leverage, revenue decline, OTC listing, delayed rescheduling), or (b) a temporary dislocation that will close as the 280E catalyst materializes and AAWH stabilizes operationally.

---

#### Bull Case — The Re-Rating Thesis

**Pillar 1: 280E Elimination Is the Dominant Catalyst**

Schedule III rescheduling (EO issued December 2025; expected finalization H1 2026) would eliminate IRC §280E for cannabis operators. For AAWH, this means:
- ~$45–50M in annual income tax expense disappears
- GAAP net income swings from $(118)M (FY2025) to potentially breakeven or modest profit
- GAAP profitability unlocks institutional capital that is currently restricted from cannabis OTC stocks
- Multiple expansion from ~2.1x to sector median 4–5x EV/Adj. EBITDA implies 90–140% upside from current EV, or $1.10–$1.75/share
- Analyst price targets of $1.75–$2.28 largely embed this re-rating scenario

Sources: Industry press releases; GuruFocus analyst targets; consensus estimates [S1]

**Pillar 2: Debt Refinanced, No Near-Term Maturity**

AAWH's $235M senior notes are due July 2029. Every major MSO peer faces debt maturities in 2026 (Curaleaf $460M, Trulieve $390M, Verano $350M). If distressed refinancings force competitor asset sales, AAWH could acquire markets/licenses at distressed prices. The debt safety margin is a relative competitive advantage.

Sources: 10-K FY2024 debt footnote; competitive landscape file [S2]

**Pillar 3: Ohio Adult-Use is Under-Appreciated**

Ohio adult-use cannabis launched December 2023. AAWH reported a ~3x increase in Ohio sales volume in 2024. Ohio's market is still in early growth phase (licensed operations just scaling up). As Ohio matures over 2025–2027, it could become AAWH's highest-revenue state — particularly given AAWH's established cultivation + retail presence.

Sources: FY2024 10-K Ohio commentary; press releases [S3]

---

#### Bear Case — The Value Trap Thesis

**Pillar 1: Revenue Decline is Structural, Not Cyclical**

AAWH's FY2025 revenue declined -10.9% to $500.6M. Q1 2026 continued the trend at -8.7% YoY. Bears argue this is not a market-timing issue but reflects structural over-supply in AAWH's core markets (Illinois in particular is widely acknowledged as over-licensed). Without a new major adult-use market opening, AAWH's revenue may be permanently lower than the FY2024 peak.

Supporting data: Illinois cannabis market has seen persistent price compression since 2022; Michigan (open license) is structurally oversupplied. These two markets may represent 40%+ of AAWH's volume.

Sources: 10-K FY2024/FY2025 MD&A; industry/competitive_landscape.md [S4]

**Pillar 2: FCF Collapse Creates Solvency Risk**

FY2025 FCF declined to ~$12M from ~$43M in FY2024. Q1 2026 saw $24.8M cash outflow (seasonal + capex + interest). Annual interest expense (~$51M) exceeds FY2025 FCF ($12M). If revenue continues declining:
- FY2026 FCF could turn negative
- Cash could decline below $30M by end of 2026
- AAWH might need to raise dilutive equity at $0.55/share (catastrophic for existing shareholders)

Sources: XBRL cash balances; press release FCF data [S5]

**Pillar 3: 280E Catalyst May Be Further Away Than Hoped**

Rescheduling has been "imminent" since 2023. Administrative law challenges, congressional opposition, and DEA procedural requirements could push finalization into 2027 or later. If 280E persists 2 more years, AAWH burns $90–100M in taxes on an already-distressed balance sheet. The bear case requires only that the catalyst is late — not that it never arrives.

Sources: Industry market overview; regulatory timeline discussion [S6]

---

#### Battleground Issues

| Issue | Bull View | Bear View |
|-------|-----------|-----------|
| Revenue trajectory | Ohio + PA adult-use stabilize at ~$490–520M by FY2027 | Structural decline to $450M range by FY2027 |
| 280E elimination timing | H2 2026 — legal challenges resolved | 2027 or later — administrative delays |
| FCF FY2026 | Stable at $10–15M; EBITDA margins hold | Negative; equity raise required |
| Valuation multiple | 3–4x EV/EBITDA post-rescheduling = $1.00–1.50/share | Stays 2x; OTC discount is permanent |
| Leverage | Manageable to 2029 | Covenant breach possible if EBITDA declines |

---

#### Bull Case — 3 Bullets

1. **280E elimination adds $45–50M of annual after-tax cash flow** — the single largest near-term catalyst for any US cannabis company; with EO issued Dec 2025, finalization is the base case for H1–H2 2026, and AAWH's $116M Adj. EBITDA base becomes a clean economic earnings stream post-rescheduling.
2. **Debt refinanced to July 2029 at fixed 9.5%** — while sector peers face $350–460M maturities in 2026, AAWH has no debt maturity risk for 3+ years, allowing it to outlast the current industry distress cycle and potentially acquire distressed competitor assets.
3. **Ohio adult-use is a multi-year tailwind still in early innings** — AAWH's established Ohio presence (cultivation + retail) positions it to benefit from Ohio's continuing adult-use ramp, which alone could add $30–50M in incremental revenue by 2026–2027 as market penetration increases.

#### Bear Case — 3 Bullets

1. **Revenue decline is structural in AAWH's core markets (Illinois, Michigan)** — both are mature/over-supplied, and without a major new adult-use market opening in the portfolio, topline revenue may continue declining toward $450M, compressing Adj. EBITDA toward $100M and narrowing the already-thin FCF to zero.
2. **FCF collapse ($43M FY2024 → $12M FY2025 → potential negative FY2026) creates an existential solvency risk** — if FCF turns negative, AAWH will need to raise equity at $0.55/share (or lower), diluting existing shareholders by 20–40% and destroying the recovery thesis.
3. **280E rescheduling is a repeated delayed catalyst** — the administrative process has been "imminent" since 2023; legal challenges, DEA administrative hearings, and congressional opposition could push finalization to 2027+, meaning AAWH burns another $90–100M in 280E taxes that it cannot absorb without deteriorating the balance sheet further.

---

#### Thesis Tracker Update

The analyst debate is sharply polarized on timing (280E resolution) and revenue trajectory (structural vs. cyclical decline). The investment thesis is primarily a bet on (a) 280E materializing and (b) AAWH preserving enough balance sheet strength to survive until it does. Both conditions are probability-weighted medium — making this a high-conviction-required, catalyst-dependent special situation.

---

#### Source Index

| Code | Source |
|------|--------|
| S1 | GuruFocus analyst targets; industry/market_overview.md; EO December 2025 |
| S2 | 10-K FY2024 — Debt footnote; industry/competitive_landscape.md |
| S3 | 10-K FY2024 Ohio commentary; FY2024 press releases |
| S4 | 10-K FY2024/FY2025 MD&A; industry/competitive_landscape.md |
| S5 | XBRL cash balances; FY2025 PR FCF data |
| S6 | industry/market_overview.md — regulatory timeline |

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/aawh
- Full research API: GET /api/v1/research/AAWH/memo
- Coverage universe: /stocks